Epithelioid vs. Sarcomatoid vs. Biphasic: 3 Mesothelioma Cell Types That Determine Your Prognosis

Epithelioid mesothelioma accounts for approximately 70% of all diagnoses and carries the best prognosis, with median survival of 12-24 months—and up to 21.2 months when Tumor Treating Fields are combined with chemotherapy ^[1]. Sarcomatoid mesothelioma, by contrast, has a median survival of roughly 8 months, while biphasic cases fall between the two depending on the ratio of cell types present ^[2]. Your mesothelioma cell type—identified through biopsy and immunohistochemistry—is one of the single most important factors in determining treatment options, expected outcomes, and compensation planning.

What Are the Three Mesothelioma Cell Types?

The World Health Organization classifies mesothelioma into three histological subtypes based on the appearance and behavior of cancer cells under microscopic examination ^[6]. Each cell type has distinct physical characteristics, growth patterns, and responses to treatment that directly shape a patient's prognosis and treatment plan.

Epithelioid mesothelioma cells are uniform, cube-shaped, and grow in organized sheet-like patterns. These cells tend to adhere to each other rather than spreading independently, which makes tumors more contained and surgically accessible. Epithelioid is the most common type at approximately 70% of diagnoses and carries the most favorable prognosis ^[7].

Sarcomatoid mesothelioma cells are elongated and spindle-shaped, resembling the cells found in connective tissue cancers called sarcomas. These cells spread rapidly, infiltrate surrounding tissues aggressively, and resist most standard treatments. Sarcomatoid accounts for 10-15% of cases and has the worst prognosis ^[8].

Biphasic mesothelioma contains a mixture of both epithelioid and sarcomatoid cells. This mixed type accounts for 20-35% of diagnoses, and prognosis depends largely on the proportion of each cell type within the tumor ^[9].

"When a patient receives their pathology report, the cell type is one of the first things we discuss. It tells us not just how the cancer is likely to behave, but which treatments offer the greatest chance of meaningful response."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How Does Epithelioid Cell Type Affect Prognosis and Treatment?

Epithelioid mesothelioma offers the widest range of treatment options and the best survival outcomes of all three cell types. Patients with epithelioid histology are most likely to qualify for curative-intent surgery, respond to chemotherapy, and benefit from emerging treatments like immunotherapy and Tumor Treating Fields ^[10].

Standard first-line chemotherapy with cisplatin plus pemetrexed achieves response rates of 40-45% in epithelioid patients, compared to roughly 20% in sarcomatoid cases ^[11]. The STELLAR trial demonstrated that adding Tumor Treating Fields (TTFields) to standard chemotherapy extended median overall survival to 21.2 months for epithelioid patients—a result that led to FDA approval of this combination ^[12].

Surgical options for epithelioid patients include pleurectomy/decortication (P/D) and, in select cases, extrapleural pneumonectomy (EPP). Multimodal treatment combining surgery with chemotherapy and sometimes radiation has produced median survival exceeding 2 years in some series ^[13]. The organized growth pattern of epithelioid cells makes surgical resection more effective because tumors tend to remain more localized.

"Epithelioid mesothelioma patients have more options today than at any point in medical history. Between TTFields, immunotherapy, and refined surgical techniques, we're seeing patients living significantly longer than even five years ago."

— Dr. Hedy Kindler, Director of Mesothelioma Program, University of Chicago Medicine

Why Is Sarcomatoid Mesothelioma Considered the Most Aggressive?

Sarcomatoid mesothelioma has a median survival of approximately 7-8 months from diagnosis, making it the most aggressive of the three cell types ^[14]. The spindle-shaped cells spread rapidly through tissue planes, often making complete surgical resection impossible. These cells also demonstrate higher resistance to conventional chemotherapy regimens.

However, the landscape for sarcomatoid mesothelioma has shifted substantially with the approval of immunotherapy. The landmark CheckMate 743 trial showed that nivolumab plus ipilimumab produced the greatest benefit precisely in patients with non-epithelioid (sarcomatoid and biphasic) histology ^[15]. In this subgroup, median survival improved from 8.8 months with chemotherapy to 18.1 months with immunotherapy—an improvement that fundamentally changed treatment recommendations.

The National Comprehensive Cancer Network (NCCN) guidelines now recommend nivolumab plus ipilimumab as first-line treatment for non-epithelioid mesothelioma, reflecting the strength of this evidence ^[16]. This represents one of the most significant advances in sarcomatoid mesothelioma treatment in decades.

"The immunotherapy data for sarcomatoid mesothelioma has been truly practice-changing. Patients who previously had very few effective options now have a treatment that more than doubles median survival in clinical trials."

— Dr. Marjorie Zauderer, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

How Does the Biphasic Cell Ratio Determine Outcomes?

Biphasic mesothelioma prognosis is not a single number—it falls on a spectrum determined by the percentage of epithelioid versus sarcomatoid cells in the tumor ^[17]. A biphasic tumor with 80% epithelioid cells behaves more like pure epithelioid mesothelioma, while one with 80% sarcomatoid cells behaves more like sarcomatoid disease.

Research published in the Journal of Thoracic Oncology has shown that biphasic tumors with greater than 50% epithelioid component have median survival approaching that of pure epithelioid cases, while those with sarcomatoid-dominant composition have outcomes closer to pure sarcomatoid disease ^[18]. This makes accurate pathological assessment of the cell ratio critical for treatment planning.

Overall median survival for biphasic mesothelioma is approximately 12 months, placing it between epithelioid and sarcomatoid. Treatment approaches are typically guided by the dominant cell type. Patients with epithelioid-predominant biphasic tumors may be offered surgery and multimodal therapy, while sarcomatoid-predominant cases are increasingly directed toward immunotherapy ^[19].

How Do Pathologists Identify Your Mesothelioma Cell Type?

Determining mesothelioma cell type requires tissue biopsy followed by specialized laboratory testing. The process begins when a surgeon obtains a tissue sample through one of several procedures, including video-assisted thoracoscopic surgery (VATS), medical thoracoscopy, or CT-guided core needle biopsy ^[20].

A pathologist examines the tissue under a microscope to assess cell morphology—the physical shape and arrangement of cancer cells. Epithelioid cells appear as organized, cube-shaped clusters. Sarcomatoid cells appear as disorganized, elongated spindles. Biphasic tissue shows areas of both patterns within the same sample.

To confirm the diagnosis and subtype, pathologists use immunohistochemistry (IHC) panels that test for specific protein markers. According to the WHO classification criteria, key positive markers for epithelioid mesothelioma include calretinin, CK5/6, WT-1, and D2-40 ^[21]. Sarcomatoid mesothelioma often stains positive for vimentin and may lack the epithelial markers. This diagnostic workup typically requires 7-14 days from biopsy to final pathology report.

"I always tell patients that the biopsy and pathology phase—while it can feel like an agonizing wait—is one of the most critical steps. An accurate cell type determination shapes everything that follows, from the treatment plan to the clinical trials you qualify for."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How Do the Three Cell Types Compare Side by Side?

The following comparison table summarizes the key differences in frequency, survival, treatment response, and characteristics across all three mesothelioma cell types, based on current clinical data and survival statistics.

What Should You Ask Your Doctor About Cell Type?

After receiving a mesothelioma diagnosis, patients should ask their oncologist specific questions about their cell type to ensure they receive the most appropriate treatment. The following questions can help guide productive conversations with your medical team.

Essential questions include:

• What is my specific cell type, and what does the pathology report show about the IHC markers?
• If biphasic, what percentage of each cell type is present in my tumor?
• Based on my cell type, am I a candidate for surgery, and which procedure is recommended?
• Should I receive chemotherapy, immunotherapy, or a combination—and how does my cell type influence that recommendation?
• Are there clinical trials specifically for my cell type that I should consider?
• Would a second pathology opinion be valuable to confirm the cell type classification?

"The difference between epithelioid and sarcomatoid mesothelioma can completely change the recommended first-line therapy. Patients who understand their cell type are better equipped to advocate for the most effective treatment approach available."

— Dr. Anne Tsao, Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center

Getting a second opinion from a specialized mesothelioma center is particularly important for cell type confirmation. Misclassification can lead to suboptimal treatment selection. Major cancer centers with dedicated mesothelioma programs have pathologists who review hundreds of mesothelioma cases and are less likely to misidentify cell type ^[22].

Why Does Cell Type Matter for Legal Claims?

Mesothelioma cell type directly affects legal compensation because it shapes the medical and financial trajectory of the disease. Experienced mesothelioma attorneys work with medical economists and life care planners who use cell type data to calculate projected treatment costs, lost income, and quality-of-life impacts.

Patients with epithelioid mesothelioma often face longer treatment courses that include surgery, chemotherapy, and potentially years of follow-up care. These extended treatment timelines can result in higher cumulative medical expenses. Patients with sarcomatoid mesothelioma may have shorter projected survival, but the aggressiveness of the disease and limited treatment options can increase pain and suffering damages.

Cell type also affects asbestos trust fund claims. Trust fund expedited review processes may apply to patients with more aggressive cell types, allowing faster access to compensation when treatment timelines are compressed ^[23]. Understanding the relationship between cell type and compensation is one reason why patients benefit from working with attorneys who specialize exclusively in mesothelioma cases.

What New Treatments Are Changing Outcomes by Cell Type?

The treatment landscape for mesothelioma is evolving rapidly, with several advances specifically benefiting patients based on their cell type. These developments offer genuine reasons for optimism, particularly for patients with historically harder-to-treat subtypes.

Immunotherapy for non-epithelioid patients: The CheckMate 743 trial established nivolumab plus ipilimumab as a new standard of care for sarcomatoid and biphasic mesothelioma, more than doubling median survival in this subgroup ^[24]. Ongoing trials are testing combinations of immunotherapy with chemotherapy and other agents across all cell types.

TTFields for epithelioid patients: The STELLAR trial showed that adding Tumor Treating Fields to standard pemetrexed-platinum chemotherapy improved median survival to 21.2 months in epithelioid patients ^[25]. This noninvasive device delivers alternating electric fields to the tumor area through arrays worn on the chest.

Molecular-targeted therapies: Emerging drugs targeting specific genetic alterations—such as BAP1 loss and EZH2 overexpression—may offer personalized treatment options that work across cell types. Clinical trials for agents like tazemetostat (an EZH2 inhibitor) are actively enrolling patients ^[26].

"I've worked with mesothelioma patients for nearly two decades, and the last five years have brought more meaningful treatment advances than the previous fifteen combined. Immunotherapy for sarcomatoid patients and TTFields for epithelioid patients are changing what's possible."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How Can You Take Action After Learning Your Cell Type?

Once you know your mesothelioma cell type, several concrete steps can help you access the best available care and protect your legal rights.

Seek a specialist opinion. Request review of your pathology slides at a National Cancer Institute-designated cancer center with a dedicated mesothelioma program. Specialist pathologists are more accurate in cell type classification, and specialist oncologists have the most current knowledge of cell-type-specific treatments.

Explore clinical trials. Many clinical trials enroll patients based on specific cell types. The CheckMate 743 results demonstrated that non-epithelioid patients benefit substantially from immunotherapy, while other trials may target epithelioid-specific approaches. Your oncologist or a mesothelioma advocacy organization can help identify relevant trials.

Protect your legal rights. If your mesothelioma resulted from asbestos exposure, your cell type is a key factor in calculating fair compensation. A free case evaluation can help determine your eligibility for trust fund claims, litigation, and veterans benefits if you served in the military. Time-sensitive filing deadlines apply in every state, so early consultation with a mesothelioma attorney is critical.

Frequently Asked Questions About Mesothelioma Cell Types?

What is the most common mesothelioma cell type?

Epithelioid mesothelioma is the most common cell type, accounting for approximately 70% of all mesothelioma diagnoses. Epithelioid cells are uniform, cube-shaped cells that grow in organized patterns and respond best to treatment. Patients with epithelioid mesothelioma have the longest median survival at 12-24 months, with recent trials showing 21.2 months when Tumor Treating Fields are added to standard chemotherapy ^[27].

What is the survival rate for sarcomatoid mesothelioma?

Sarcomatoid mesothelioma has a median survival of approximately 7-8 months from diagnosis and accounts for 10-15% of cases. These spindle-shaped cells spread rapidly and resist standard chemotherapy. However, the CheckMate 743 trial showed that nivolumab plus ipilimumab extended median survival to 18.1 months in non-epithelioid patients, compared to 8.8 months with chemotherapy alone ^[28].

What does biphasic mesothelioma mean for treatment options?

Biphasic mesothelioma contains a mixture of both epithelioid and sarcomatoid cells, accounting for 20-35% of diagnoses. Treatment options and prognosis depend heavily on the ratio of cell types within the tumor. Tumors with a higher percentage of epithelioid cells respond more favorably to surgery and chemotherapy, while sarcomatoid-dominant tumors are increasingly treated with immunotherapy.

How do doctors determine mesothelioma cell type?

Pathologists determine mesothelioma cell type through tissue biopsy and immunohistochemistry (IHC) testing. Tissue is obtained through VATS, medical thoracoscopy, or CT-guided biopsy. Microscopic examination identifies cell morphology, and IHC panels test for specific protein markers—calretinin, CK5/6, and WT-1 for epithelioid cells and vimentin for sarcomatoid cells. Results typically take 7-14 days ^[29].

Does mesothelioma cell type affect legal compensation?

Yes, cell type significantly affects compensation because it influences life care plan costs and damages calculations. Sarcomatoid patients may qualify for expedited trust fund review due to compressed treatment timelines, while epithelioid patients may have higher cumulative medical expenses from longer treatment courses. Experienced mesothelioma attorneys use cell type data when working with medical economists to calculate appropriate damages.

Can mesothelioma cell type change over time?

Cell type classification can appear to shift, particularly in biphasic tumors where the sarcomatoid component may become more dominant as the disease progresses. Initial biopsies may also sample only one portion of a mixed tumor. Some epithelioid tumors undergo dedifferentiation toward sarcomatoid features during treatment, which is why oncologists sometimes recommend repeat biopsies if treatment response changes unexpectedly.

What new treatments show promise for sarcomatoid mesothelioma?

Immunotherapy with nivolumab plus ipilimumab has been the most significant advancement, extending non-epithelioid median survival from 8.8 to 18.1 months in the CheckMate 743 trial. CAR-T cell therapy clinical trials are also actively recruiting mesothelioma patients regardless of cell type. Additionally, molecular-targeted agents such as EZH2 inhibitors are in clinical trials and may benefit patients with specific genetic alterations ^[30].